SEC Form 4 · accession 0000899243-16-023481
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Thomas Heffernan
Director
Period of report
Jun 21, 2016
Accepted (ET)
Jun 23, 2016 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1 | $6.05 | Jun 21, 2016 | A | 50,000 | A | Jun 21, 2017 | Jun 21, 2026 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The 50,000 stock options vest as follows: 16,667 on June 21, 2017; 16,667 on June 21, 2018; 16,666 on June 21, 2019.